SAN DIEGO, Jan. 31 /PRNewswire/ -- MediVas, LLC, a developer of novel drug delivery platforms, today announced the signing of an exclusive technology evaluation and exclusive option agreements with Merck & Co., Inc. The agreements focus on several orally available biologics delivered using MediVas’ proprietary polymer delivery system.
Under the terms of the agreement, MediVas will receive an upfront cash payment as well as research funding and milestones during the evaluation period. Financial terms were not disclosed.
“We are pleased to partner with Merck, whose leadership in the area of biologics makes them an ideal partner for MediVas,” said Kenneth W. Carpenter, MediVas’ President and CEO. “MediVas’ novel polymer platforms have the potential to shift the paradigm of biologics delivery and open the door for a novel generation of therapeutics.”
About MediVas: Using its proprietary family of biodegradable and biocompatible polymers, MediVas has developed unique platforms for the delivery of biologics. MediVas is utilizing its novel polymer technology in collaboration with some of the world’s largest pharmaceutical companies, as well as on its own internal product development efforts, to create groundbreaking medical advancements. By combining therapeutic proteins and other biologics with a MediVas polymer, delivery routes that were previously unattainable, such as oral, intranasal, inhaled or subcutaneous injection, can now be achieved. With these routes of delivery then available, MediVas’ delivery system can make the administration of the biologic more convenient, more efficacious and safer, leading to higher patient compliance and overall better health.
Contact: MediVas, LLC Victor E. Vilaplana Director, Business Development (858) 622-2005 vvilaplana@medivas.com
MediVas, LLC
CONTACT: Victor E. Vilaplana, Director, Business Development of MediVas,LLC, +1-858-622-2005, vvilaplana@medivas.com
